Update on Plans to Strengthen Balance Sheet
Updated : 11:35
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
REDX PHARMA PLC
("Redx" or "the Company" or "the Group")
Update on Plans to Strengthen Balance Sheet
Alderley Park, 3 May 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, is today providing an update on its ongoing plans to strengthen the Group's balance sheet.
As highlighted in the final results announcement released on 19 November 2018, the Board is committed to strengthening the Group's balance sheet in order to extend the cash runway beyond the second quarter of 2019.
Since then various management actions, coupled with the previously announced receipt of a loan repayment, have extended the cash runway into July of this year. Furthermore, in recognition of the need to conserve cash, the Group has initiated specific measures to reduce the company's operational cost base.
In addition, the Board is looking to further strengthen the Group's short-term financial position through two specific initiatives: short-term convertible debt financing and potential value realisation of the pan-RAF research programme through outlicensing.
The Board continues to be in active discussions with shareholders and third-party healthcare specialist investors regarding longer-term funding of the Group.
The Board is greatly encouraged by the advanced state and positive nature of these various initiatives, although more time is required to conclude them and there is no guarantee that any of them will be concluded. Further announcements will be made in due course.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer Iain Ross, Chairman |
|
|
|
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin |
|
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.